1377049-84-7

Basic information

• Product Name: Velpatasvir
• Synonyms: Velpatasvir;velpatasvir(GS-5816);methyl ((2s)-1-((2s,5s)-2-(9-(2-((2s,4s)-1-((2r)-2-((methoxycarbonyl)amino)-2-phenylacetyl)-4-(methoxymethyl)pyrrolidin-2-yl)-1h-imidazol-5-yl)-1,11-dihydroisochromeno(4',3':6,7)naphtho(1,2-d)imidazol-2-yl)-5-methylpyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate;Velpatasvir API;Unifiram (DM-232);Methyl [(2S)-1-[(2S,5S)-2-[9-[2-[(2S,4S)-1-[(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl]-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yl]-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-y;MFCD28411371;Product:Velpatasvir
• CAS NO: 1377049-84-7
• Molecular Formula: C₄₉H₅₄N₈O₈
• Molecular Weight: 883.00186
• EINECS: 1592732-453-0
• Mol File: 1377049-84-7.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Density: 1.314±0.06 g/cm3(Predicted)
• Storage Temp.: -20°C
• Solubility: Soluble in DMSO (>25 mg/ml)
• PKA: 10.75±0.46(Predicted)
• Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
• CAS DataBase Reference: Velpatasvir(CAS DataBase Reference)
• NIST Chemistry Reference: Velpatasvir(1377049-84-7)
• EPA Substance Registry System: Velpatasvir(1377049-84-7)

Safety Data

• Hazardous Substances Data: 1377049-84-7(Hazardous Substances Data)

Usage

Description

Velpatasvir is an extremely potent pan-genotypic hepatitis C virus (HCV) NS5A inhibitor, playing a crucial role in the treatment of patients with chronic hepatitis C of all six major genotypes. It is a component of Epclusa and Vosevi, two clinically useful medications with high cure rates for HCV. Velpatasvir has demonstrated an excellent barrier to viral resistance and has shown potential as a therapeutic for SARS-CoV-2.

Uses

Used in Pharmaceutical Industry:
Velpatasvir is used as an NS5A inhibitor for the treatment of patients with hepatitis C (HCV) infection. It is a key component in the medications Epclusa and Vosevi, which have shown high cure rates (98% and 97%, respectively) for HCV. Velpatasvir's potent action against HCV and its ability to inhibit various genotypes make it a valuable asset in the fight against the virus.
Additionally, Velpatasvir has been identified through in silico studies as a potential therapeutic agent for SARS-CoV-2, the virus responsible for the COVID-19 pandemic. This suggests that Velpatasvir could have applications in the development of treatments for other viral infections as well.

References

Link et al. (2019), Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi? and Epclusa?; Bioorg. Med. Chem. Lett., 29 2415 Kadioglu et al. (2020), Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning; Comput. Biol. Med. 133 104359

Upstream product

• 1378391-39-9 (2S,4S)-1-tert-butyl 2-(2-oxo-2-(8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)ethyl) 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate 
• 1378391-42-4 (2S,4S)-2-(2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)-2-oxoethyl) 1-tert-butyl 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate 
• 1378391-43-5 (2R,4R)-1-tert-butyl 2-(2-(9-((2S,5S)-1-((S)-2-(methoxycarbonylamino)-3-methylbutanoyl)-5-methylpyrrolidine-2-carbonyloxy)-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)-2-oxoethyl) 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate 
• 1378391-44-6 tert-butyl (2S,4S)-2-[5-(2-{(2S,5S)-1-[N-(methoxycarbonyl)-L-valyl]-5-methylpyrrolidin-2-yl}-1,4,5,11-tetrahydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-9-yl)-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidine-1-carboxylate 
• 1378391-45-7 tert-butyl (2S,4S)-2-[5-(2-{(2S,5S)-1-[N-(methoxycarbonyl)-L-valyl]-5-methylpyrrolidin-2-yl}-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-9-yl)-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidine-1-carboxylate 
• 50890-96-5 (2R)-2-[(methoxycarbonyl)amino]-2-phenylacetic acid 
• 487048-28-2 (2S,4S)-4-cyano-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 
• 1378388-30-7 (2S,4S)-N-(tert-butyloxycarbonyl)pyrrolidine-2,4-dicarboxylic acid dimethyl ester 
• 1378388-35-2 (3S,5S)-N-(tert-butoxycarbonyl)-5-(methoxycarbonyl)-pyrrolidine-3-carboxylic acid 
• 1194059-42-1 (2S,4S)-N-(tert-butyloxycarbonyl)-4-(hydroxymethyl)-pyrrolidine-2-carboxylic acid methyl ester 
• 1378393-23-7 C₁₅H₂₃NO₈ 
• 1378388-37-4 (2S,4S)-N-(tert-butyloxycarbonyl)-4-(methoxymethyl)-pyrrolidine-2-carboxylic acid methyl ester 
• 1378388-16-9 (2S,4S)-N-(tert-butyloxycarbonyl)-4-(methoxymethyl)-pyrrolidine-2-carboxylic acid 

Relevant articles and documents

Method for preparing NS5A inhibitor-Velpatasvir

The invention discloses a method for preparing an NS5A inhibitor-Velpatasvir, wherein the method mainly comprises the five steps: 1) carrying out docking reaction on reaction initial raw materials VPM1, VPM2 and VPM3 under the catalytic action of alkali to prepare an intermediate VP1; 2) removing amino protecting groups from the intermediate VP1 by using a protecting group removing reagent to prepare an intermediate VP2; 3) carrying out cyclization on the intermediate VP2 and an amine compound to prepare an intermediate VP3; 4) carrying out a reaction on the intermediate VP3 with VPM4 under the action of a condensing agent to prepare an amide compound intermediate VP4; and 5) carrying out oxidation reaction on the intermediate VP4 under the action of an oxidizing agent to prepare Velpatasvir. The preparation process of Velpatasvir has the characteristics of simplified route, simple reaction conditions, enhanced operability and higher product yield, and is more suitable for large-scaleindustrial production.

Compound used for inhibiting hepatitis C virus, and pharmaceutical applications thereof

The invention relates to a compound which is represented by formula I, is used for inhibiting hepatitis C virus, and possesses excellent bioavailability, and a nontoxic pharmaceutically acceptable salt thereof. The compound possesses extremely high inhibition effect on HCV of all genotypes. In the formula I, R is used for representing hydrogen atom, glycyl, L-alanyl, L-leucyl, L-valyl, or L-isoleucyl.

Preparation of velpatasvir and derivatives thereof

The invention relates to a preparation method of velpatasvir and derivatives thereof. Concretely, the preparation method provided by the invention comprises the step of preparing the velpatasvir and derivatives thereof (definitions of all the groups are described in the specification) by virtue of an intermediate compound shown in a formula. The preparation method provided by the invention has the advantages that byproducts are fewer, cost is low, and the preparation method is applicable to industrial production of velpatasvir. (The formula is described in the specification.).